| Drug Name |
Rituximab |
| Drug ID |
BADD_D01953 |
| Description |
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences [A40017], [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. |
| Indications and Usage |
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. |
| Marketing Status |
Prescription |
| ATC Code |
L01FA01 |
| DrugBank ID |
DB00073
|
| KEGG ID |
D02994
|
| MeSH ID |
D000069283
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D09EXD
|
| NDC Product Code |
71124-0003; 50242-053; 50242-051; 50242-052 |
| Synonyms |
Rituximab | CD20 Antibody, Rituximab | Rituximab CD20 Antibody | Mabthera | IDEC-C2B8 Antibody | IDEC C2B8 Antibody | IDEC-C2B8 | IDEC C2B8 | GP2013 | Rituxan |
